Abstract
Background
Mild cognitive impairment represents a critical precursor stage for dementia, and the search for reliable blood biomarkers is essential for early detection and intervention.
Objective
This study aimed to explore the relationship between serum levels of amyloid-β (Aβ)1−42 and p-tau181 proteins and mild cognitive impairment (MCI), providing a foundation for early detection of MCI.
Methods
A total of 128 qualified subjects aged 60 years or above were enrolled according to the inclusion and exclusion criteria at Yangpu Hospital of Tongji University, Shanghai, China, between June 2021 and December 2022. Serum levels of Aβ1−42 and p-tau181 were measured using enzyme-linked immunosorbent assay (ELISA). Participants were divided into MCI and non-MCI groups based on clinical diagnostic criteria. Statistical analyses were conducted using chi-square tests to evaluate demographic variables, while Mann-Whitney U tests were employed to compare protein levels between groups. Additionally, Spearman correlation analysis was utilized to examine the relationship between protein levels and MCI.
Results
The MCI group exhibited significantly higher serum levels of Aβ1−42 (U = 3959.0, p < 0.001) and p-tau181 (U = 3032.5, p < 0.001) compared to the non-MCI group. A strong positive correlation was found between Aβ1−42 levels and MCI (r = 0.819, p < 0.001), while a moderate correlation was observed for p-tau181 (r = 0.426, p < 0.001). Aβ1−42 demonstrated high diagnostic value (AUC = 0.975, 95%CI 0.954–0.997; p < 0.001) at its optimal cutoff 105.37 pg/mL, and p-tau181 exhibited moderate diagnostic efficacy (AUC = 0.747, 95%CI 0.658–0.836; p < 0.001) at its optimal cutoff 12.07 pg/mL.
Conclusions
Serum levels of Aβ1−42 and p-tau181 are associated with MCI and may serve as potential biomarkers for early detection.
Get full access to this article
View all access options for this article.